PharmaCyte Biotech : Presentation of PharmaCyte Biotech
September 17, 2021 at 10:32 pm IST
Share
Safe Harbor Statement and Disclaimer
This document may include statements by PharmaCyte Biotech that constitute
"forward-looking statements." Such statements are often characterized by the terms "may," "believes," expects" or "anticipates" and do not reflect facts.
Forward-lookingstatements involve risks, uncertainties and other factors that may cause actual results, performance or achievements of PharmaCyte and its subsidiaries to be materially different from those expressed or implied by such forward-looking statements. Forward-looking statements speak only as of the date the statement was made. PharmaCyte does not undertake, and specifically declines, any obligation to update any forward-looking statements.
Factors that may affect forward-looking statements and PharmaCyte's business generally including, but not limited to: (i) the risk factors, cautionary and other statements set forth in PharmaCyte's periodic filings with the Securities and
Exchange Commission available at www.sec.gov, and (ii) other factors that PharmaCyte is currently unable to identify or quantify but may exist in the future.
2
Safe Harbor Statement and Disclaimer (cont'd)
This presentation shall not constitute an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
3
Platform Technology for Cancer and Diabetes
Encapsulate Genetically Modified Live Cells to Treat Diseases
Cancer:
Encapsulated cells convert a prodrug from its inactive form to its cancer- killing form
Encapsulated cells are implanted near the site of the tumor; low dose chemotherapy prodrug is given intravenously. Encapsulated cells act as an artificial liver to convert the prodrug at the site of the tumor
We believe that this technology results in optimal cytotoxic effect with little to no treatment-related side effects
Diabetes:
Encapsulated cells that produce, store, and release insulin in response to
concentrations of glucose in the body are employed
Encapsulated cells are implanted to act as an artificial pancreas for insulin production
4
Pipeline
Pancreatic Cancer:
Encapsulated live cells converting
Preclinical
Phase 1
Phase 2b
Phase 3
Ifosfamide - antitumor effectiveness
and good quality of life*
Ascites Fluid Accumulation:
Encapsulated live cells converting
Preclinical
Phase 1
Phase 2
Phase 3
Ifosfamide - delaying malignant ascites
fluid accumulation
Diabetes:
Encapsulated live cells producing
Preclinical
Phase 1
Phase 2
Phase 3
insulin on demand for Type 1 and
Type 2 diabetes
Cancer Using Cannabinoids:
Encapsulated live cells converting
Preclinical
Phase 1
Phase 2
Phase 3
cannabinoid prodrugs - antitumor
effectiveness and pain control
5
*Our planned Phase 2b clinical trial has been placed clinical hold by the FDA, subject to PharmaCyte satisfying the FDA's concerns. The dark blue
shading indicates the current status of the Company's development program.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original document
Permalink
Disclaimer
PharmaCyte Biotech Inc. published this content on 17 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 September 2021 17:01:09 UTC.
PharmaCyte Biotech, Inc. is a biotechnology company. It is focused on developing cellular therapies for cancer, diabetes, and malignant ascites based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. Its product candidate is referred to as CypCaps. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used to produce various biologically active molecules. It is advancing clinical research and development of new cellular-based therapies in oncology and diabetes. It is also focused on developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells. Its product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. It is also focused on the benefits of the Cell-in-a-Box technology to develop therapies for cancer that involve prodrugs based upon certain constituents of the Cannabis plant.